Assenagon Asset Management S.A. Buys 1,728,480 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Assenagon Asset Management S.A. boosted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 2,418.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,799,944 shares of the life sciences company's stock after acquiring an additional 1,728,480 shares during the period. Assenagon Asset Management S.A. owned 2.33% of Integra LifeSciences worth $39,581,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in IART. Quadrant Capital Group LLC raised its holdings in shares of Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after purchasing an additional 1,371 shares during the period. Sterling Capital Management LLC increased its holdings in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after acquiring an additional 1,931 shares during the period. Covestor Ltd increased its holdings in shares of Integra LifeSciences by 61.8% in the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after acquiring an additional 2,071 shares during the period. Empowered Funds LLC acquired a new stake in shares of Integra LifeSciences in the 4th quarter worth about $180,000. Finally, NorthRock Partners LLC acquired a new stake in shares of Integra LifeSciences in the 4th quarter worth about $251,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IART has been the topic of a number of analyst reports. Wells Fargo & Company dropped their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. JMP Securities reduced their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. JPMorgan Chase & Co. reduced their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, Truist Financial reduced their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Four analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $18.63.

Integra LifeSciences Stock Down 4.2%

NASDAQ:IART traded down $0.53 during mid-day trading on Friday, reaching $12.16. The stock had a trading volume of 954,244 shares, compared to its average volume of 1,045,717. The stock has a market cap of $944.98 million, a P/E ratio of -135.10, a PEG ratio of 0.73 and a beta of 1.16. The business's 50 day moving average is $14.50 and its 200 day moving average is $20.18. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a fifty-two week low of $11.60 and a fifty-two week high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). The business had revenue of $382.65 million for the quarter, compared to the consensus estimate of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences's revenue was up 3.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.55 EPS. As a group, sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.